The combination of AZD5363 with the antiandrogen bicalutamide results in synergistic inhibition of cell proliferation and induction of apoptosis in vitro, and prolongation of tumor growth inhibition and PSA stabilization in CRPC in vivo [20]. The gene discussed is KLK3; the disease is neoplasm.